Because not every NSCLC patient benefits from first‐ and second‐generation EGFR‐TKIs due to the development of T790M mutation‐mediated resistance, a third‐generation EGFR‐TKI, namely, Osimertinib, has been developed. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.